Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Nasal vs IV Ondansetron in Healthy Adults
NCT07868861Phase 1Recruiting
- Sponsor
- Nasus Pharma
- Start
- Sep 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of ondansetron in chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV) and postoperative nausea and vomiting (PONV) (3 arms), sponsored by Nasus Pharma. Primary endpoints: Ondansetron plasma concentrations over time, Maximum Plasma Concentration and 5 more. Started Sep 2026; status: recruiting.
02
Drugs
ondansetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)radiotherapy-induced nausea and vomiting (RINV)postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT07868861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07868861.